Shares in ACW are this morning trading up over 200% from their closing price yesterday. The company released an update regarding their Xanamem product.
The key points the company focused on in the release were.
- Statistically significant results demonstrate cognitive improvement in healthy elderly subjects dosed with 20mg Xanamem daily in the XanaHES dose escalation study - Statistically significant reduction in serum cortisol following treatment with Xanamem 20mg daily -Xanamem 20mg daily continues to exhibit a good safety profile with no serious adverse events observed -Results significantly enhance the Xanamem dataset and help shape Actinogen’s drug development strategy for the treatment of Alzheimer’s disease and other neurological and metabolic diseases associated with cognitive impairment - Company to host a Conference Call on October 1st, 2019 (today) at 10:30am (AEST)